We help you manage the flood of tests and drugs that emerge in this category daily. Accessed through the Hayes Knowledge Center, our comprehensive Precision Medicine solution focuses on thousands of genetic, genomic, and molecular diagnostic tests and precision medicine therapies addressing the questions our clients most frequently ask:
The report evaluates the analytical validity, clinical validity, and clinical utility of the ColonSentry liquid biopsy test, a gene expression assay intended to estimate the current relative risk of having colorectal cancer (CRC) for patients eligible for CRC screening.
This report evaluates the analytical validity, clinical validity, and clinical utility of the FilmArray Respiratory Panel.
This report evaluates the analytical validity, clinical validity, and clinical utility of the Oncotype DX Breast Recurrence Score test.
This report evaluates the clinical utility of pharmacogenetic and pharmacogenomic testing for (1) gene variants to predict risk of opioid dependency in patients being treated for pain or (2) gene variants to improve treatment of patients with diagnosed opioid use disorder (OUD).
This report evaluates the analytical validity, clinical validity, and clinical utility of the Oncotype DX Breast Recurrence Score testfor patients diagnosed with estrogen receptor–positive, human epidermal growth factor 2–negative, and node-negative invasive breast cancer.
This report evaluates the clinical utility of liquid biopsy tests for colorectal cancer (CRC) screening to reduce CRC morbidity and mortality.
This report evaluates the analytical validity, clinical validity, and clinical utility of the FilmArray Respiratory Panel 2.
This report evaluates the analytical validity, clinical validity, and clinical utility of the Envisia Genomic Classifier.
This report evaluates the clinical utility of pharmacogenetic testing for CYP2D6 gene variants prior to prescribing codeine or tramadol to improve opioid treatment–related outcomes in pediatric patients with organic causes of pain.
This report evaluates the clinical utility of pharmacogenetic testing for CYP2D6 gene variants prior to prescribing codeine or tramadol to improve opioid treatment–related outcomes in pediatric patients with organic causes of pain.